Oncology
Acute Lymphoblastic Leukaemia
0
Pipeline Programs↗
7
Active Trials↗
5
Companies Involved↗
Acute Lymphoblastic Leukaemia is an early-stage landscape with 0 programs across 5 companies. The most active players are Sanofi, Institut de Recherches Internationales Servier, Amgen.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
22
clinical trials
Completed8 · 36%
Unknown status5 · 23%
Recruiting4 · 18%
Active, not recruiting2 · 9%
Terminated2 · 9%
Not yet recruiting1 · 5%
Clinical Trials
Trial Activity
22 trials
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Recruiting·—·Phase 3·NCT04307576·6,430 enrolled
The Association Between Asparaginase Enzyme Activity Levels and Toxicities in Childhood Acute Lymphoblastic Leukaemia in NOPHOALL 2008
Completed·—·N/A·NCT04187248·1,248 enrolled
TT52CAR19 Therapy for B-cell Acute Lymphoblastic Leukaemia (B-ALL)
Completed·GGreat Ormond Street Hospital for Children NHS Foundation Trust·Phase 1·NCT04557436·9 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)